EDGAR·FLOW

CorMedix Inc. — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
CorMedix Inc. agreed to purchase Heron Therapeutics' business assets (pharmaceutical products in chemotherapy-induced nausea, post-operative nausea/vomiting, and post-operative pain) for Base Cash Consideration of $145,000,000, plus 14,583,333 shares of Buyer Common Stock, plus contingent royalty and earn-out payments. Transaction dated November 8, 2026, requires Seller stockholder approval and antitrust clearances. Buyer is financing via Loan Agreement with BioPharma Credit entities. Purchase price adjustable based on working capital (Target: $102,000,000) with $2,000,000 escrow.
Why this rating

Large acquisition (~$145M cash + equity) at ~16% of CorMedix's $909.7M market cap is material, adds established product portfolio and revenue stream, though integration risk exists.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$5.48 ▲ 3.59%
at our read · unknown
$5.29
+10 min · unknown
$5.24 ▼ 0.95%
+30 min · unknown
$5.38 ▲ 1.70%
+1 hr · unknown
$5.51 ▲ 4.16%
+4 hrs · unknown
$5.42 ▲ 2.55%

The stock had already moved -3.47% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ CRMD · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.